Other
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
Next-Generation IL-2 Superkine Developer
Executive Summary
- Event: First patient dosed in the NEO-CYT study (Phase 1b randomized, multi-centre trial).
- Drug: MDNA11 (long-acting IL-2 Superkine) combined with nivolumab +/- ipilimumab.
- Indication: High-risk, surgically resectable Stage III cutaneous melanoma (neoadjuvant setting).
- Sponsor: Fondazione Melanoma Onlus; Lead Investigator: Prof. Paolo A. Ascierto.
- Context: Extends MDNA11 development beyond metastatic setting (ABILITY-1) to earlier-stage cancer where immune system is more intact.
- Timeline: Interim data anticipated H2 2026.
- Financial Context: Cash runway previously reported as extending into Q3 2026 (as of Dec 31, 2025).
Material Impact
- Expectation vs. Reality: The initiation of the NEO-CYT trial was announced in November 2025 with enrollment planned for H1 2026. This news confirms execution on schedule rather than introducing a surprise milestone.
- Strategic Shift: Moving MDNA11 into neoadjuvant therapy is strategically significant as it targets patients prior to surgery, potentially offering curative intent and expanding the addressable market compared to metastatic-only indications. However, without efficacy data (pathologic response rates), this remains a potential upside rather than realized value.
- Capital Needs: The company reported $10.6M cash at Dec 31, 2025, with runway into Q3 2026. As of May 2026, the company is approaching the end of its current cash runway without a new financing or partnership announcement in this release. This creates immediate dilution risk.
- Market Reaction: The stock has declined significantly from $1.64 (Dec 2025) to $0.66 (May 2026), suggesting the market is pricing in execution risks and capital concerns rather than celebrating the trial start.
- Verdict: Positive for pipeline progression but neutral on immediate financial health or valuation expansion due to lack of efficacy data and pending capital needs.
MDNA · Price
Company Overview
- Company: Medicenna Therapeutics Inc.
- Flagship Asset: MDNA11 (IL-2 Superkine). Designed to preferentially activate CD8+ T cells and NK cells while sparing regulatory T cells ("beta-enhanced not-alpha").
- Pipeline Assets:
- MDNA113: First-in-class anti-PD-1 x IL-2 bifunctional Superkine (Preclinical, IND expected H2 2026).
- Bizaxofusp (MDNA55): IL-4 Empowered Superkine for Glioblastoma (Phase 2b completed with strong OS data).
- Development Stage: MDNA11 is in Phase 1/2 clinical trials; NEO-CYT moves it to neoadjuvant setting. Bizaxofusp seeks partnership.
More from MEDICENNA THERAPEUTICS CORP. J
Jun 26, 2026 · 08:45